Clinical Trial

A new clinical trial is underway for a next-gen aortic valve, promising a less invasive procedure and improved durability for millions of patients.

With stellar trial data for its cholesterol drug obicetrapib, NewAmsterdam Pharma faces investors as it navigates a competitive market and awaits key results.

KingstronBio's successful implant of its advanced ProStyle M® heart valve kicks off a key study, signaling a new era for patients and China's medtech.

With its future riding on a pivotal trial for avexitide, Amylyx's upcoming conference presentation offers a crucial look into its post-ALS strategy.

Following positive safety data, Phanes Therapeutics expands trials for spevatamig, a first-in-class antibody targeting two cancer pathways at once.

Early Phase 3 results show gotistobart dramatically extends survival for lung cancer patients with limited options, heralding a potential new standard of care.

A US-Uruguay collaboration is using novel REJOIN-seq tech to find hidden RNA triggers of lupus, paving the way for safer, non-immunosuppressive drugs.

AIRNA has dosed the first patient with AIR-001, an RNA-editing drug that could treat both the lung and liver damage of a devastating genetic disease.

A new trial for advanced liver cancer tests visugromab, a drug aiming to overcome immunotherapy resistance and reverse debilitating cancer-related wasting.

A new botanical drug candidate, NFL-102, targets the deep neural roots of addiction, moving beyond symptom management to offer a lasting cure for smokers.

A groundbreaking trial testing if a coffee infused with an ancient herb can slow prostate cancer recurrence is nearing completion, offering hope for a new era.

A long-acting ketamine injection shows promise in treating severe depression without the harsh side effects and monitoring, potentially expanding access for millions.

With record revenue and A-list fans, British MedTech firm LYMA is doubling down on the US market, blending clinical data with celebrity appeal.

A $10M investment from BVF Partners propels Entera Bio’s revolutionary oral osteoporosis drug into a pivotal Phase 3 trial, a major step for patients.

With promising clinical data, Clarametyx promotes key executives to accelerate its novel attack on chronic respiratory disease biofilms. Jennifer Anderson reports.

A novel triple-action topical spray for male pattern baldness enters a pivotal clinical trial, potentially disrupting a multi-billion dollar market.

AvenCell has dosed the first patient with AVC-203, a novel allogeneic CAR-T therapy, aiming to make advanced cancer treatment more accessible and effective.

A breakthrough test for Parkinson's is expanding worldwide, promising earlier, more accurate diagnoses and accelerating the hunt for a cure.

AskBio completes enrollment for a pivotal Phase 2 trial of a one-time gene therapy, potentially revolutionizing treatment for millions with heart failure.

Abbisko's irpagratinib gets EMA Orphan Drug status, fast-tracking a precision therapy for a hard-to-treat liver cancer subgroup with unmet needs.